login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Symplicity Renal Denervation System receives Health Canada licence


Wednesday, 18 Apr 2012 15:07
Renal denervation
Renal denervation

Medtronic  has announced that it has received a Health Canada licence for its Symplicity Renal Denervation System to reduce treatment-resistant high blood pressure in patients unresponsive to three or more anti-hypertensive medications. 


“Decreasing a patient’s systolic blood pressure from 160 to 130 mm Hg over a period of six months, which renal denervation has been shown to do, could prevent many heart attacks and strokes from ever happening,” said Barry Rubin, medical director, Peter Munk Cardiac Centre, Toronto, Ontario. “Our multidisciplinary renal denervation programme, which includes interventional radiologists, vascular surgeons, cardiologists, hypertension and kidney specialists will treat many eligible patients in the months ahead.”

Results from the SYMPLICITY HTN-1 trial have shown sustained safety and effectiveness of renal denervation with the system out to three years, and results from the SYMPLICITY HTN-2 trial showed safe, and statistically significant reduction of blood pressure (-33 mg Hg systolic blood pressure) at six months following the procedure and sustained to 12 months. These data were recently presented at the annual American College of Cardiology during an oral session, which was dedicated to renal denervation.


In addition to the licence from Health Canada, the Symplicity Renal Denervation System has received CE mark and a listing with Australia’s Therapeutic Goods Administration (TGA). The Symplicity Renal Denervation System is under investigational use in the United States.


About the Symplicity Renal Denervation System


The Symplicity Renal Denervation System accomplishes renal denervation via a minimally invasive procedure that disables sympathetic nerves located in the renal artery walls, which has been shown to reduce high blood pressure. The system consists of a generator and a flexible catheter. The catheter is introduced through the femoral artery in the upper thigh and is threaded up into the renal artery near each kidney. Once in place, the tip of the catheter delivers low-power radiofrequency energy according to a proprietary algorithm, or pattern, to ablate the surrounding sympathetic nerves. The procedure does not involve a permanent implant.




Add New Comment

Related Items


Most popular


Tuesday, 12 Aug 2014
Toshiba has announced that it will feature SURESubtraction Coronary at The European Society of Cardiology (ESC) congress (30 August–3 September, Barcelona, Spain). Toshiba Introduces SURESubtraction Coronary at ESC 2014

Friday, 04 Jul 2014
A new study suggests that transradial access in patients with non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention is associated with reduced bleeding ... Transradial access predicts survival in NSTEMI patients

Friday, 22 Aug 2014
Royal Philips has announced that it has received 510(k) clearance from the US Food and Drug Administration to market its precision planning application for transcatheter aortic-valve implantation (TAV... FDA 510(k) clearance for TAVI precision treatment planning application

Features


Transitioning from transfemoral to transradial: Why the transradial approach is here to stay
Thursday, 21 Aug 2014
William H Crowder believes that, despite some US interventional cardiologists’ reluctance to use the approach, the transradial approach will become standard of care for coronary catheterisation ... Transitioning from transfemoral to transradial: Why the transradial approach is here to stay

The role of rotational atherectomy in contemporary PCI practice
Thursday, 07 Aug 2014
James Cockburn, David Hildick-Smith, and Adam de Belder describe their recent study (published in the International Journal of Cardiology), which found that patients who underwent rotational ... The role of rotational atherectomy in contemporary PCI practice

Profiles


David J Cohen
Wednesday, 04 Jun 2014
David J Cohen, director, Cardiovascular Research, Saint Luke’s Mid America Heart Institute, Kansas C... David J Cohen

Ashok Seth
Wednesday, 12 Feb 2014
Ashok Seth is the immediate past president of Cardiological Society of India and is the principal ... Ashok Seth

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions